Highlights of weekly biotech stock moves

Amgen Inc. (NASDAQ:AMGN) gained $2.10 to $54.08 last week after FDA assigned a PDUFA date of April 26, 2012, to an sBLA for Xgeva denosumab to prevent bone metastases in men with castration-resistant prostate cancer (CRPC).

Corcept Therapeutics Inc. (NASDAQ:CORT) was off $0.08 to $2.76 last week after saying that FDA indicated that it will not convene an advisory committee meeting to discuss Corlux mifepristone for Cushing's syndrome. The PDUFA date is Feb. 17, 2012. The hormonal disorder is caused by prolonged exposure to high levels of cortisol...